A systematic review of the effectiveness of adalimumab

104
Health economics
TABLE 53 Base case: TNF inhibitors first (400,000 patients)
Option Cost (£) QSE QALYs QSE
Adal 49,538 51 8.9674 0.0084
Etan 63,892 62 9.3005 0.0088
Adal+MTX 49,650 52 8.5176 0.0080
Etan+MTX 64,079 62 8.9408 0.0085
Infl+MTX 49,079 49 8.3682 0.0080
Base 15,331 11 8.3166 0.0079
Comparison Diff. cost (£) QSE Diff. QALY QSE
Adal – Base 34,207 50 0.6508 0.0085
Etan – Base 48,561 60 0.9839 0.0087
Ad+M – Base 34,319 51 0.2010 0.0083
Et+M – Base 48,748 61 0.6242 0.0086
In+M - Base 33,748 48 0.0516 0.0083
Ad+M – Adal 112 69 –0.4498 0.0085
Et+M – Etan 187 82 –0.3597 0.0090
Etan – Adal 14,354 76 0.3332 0.0088
Et+M – Ad+M 14,429 77 0.4232 0.0086
Ad+M – In+M 571 68 0.1493 0.0083
Et+M – In+M 15,000 75 0.5726 0.0086
Comparison ICER (£ per QALY) Quasi-CI
Adal – Base 52,600 51,200 to 54,000
Etan – Base 49,400 48,500 to 50,300
Ad+M – Base 171,000 158,000 to 186,000
Et+M – Base 78,100 76,000 to 80,300
In+M – Base 654,000 495,000 to 962,000
Ad+M – Adal Adal alone more effective than Adal+MTX; diff. cost not significant
Et+M – Etan Etan alone dominates Etan+MTX
Etan – Adal 43,100 40,900 to 45,500
Et+M – Ad+M 34,100 32,700 to 35,600
Ad+M – In+M 3,830 2,820 to 4,830
Et+M – In+M 26,200 25,400 to 27,100